ABOUT

What you missed at: 2nd Oligonucleotides CMC & Analytical Development Summit 2023

The 2nd Oligonucleotides CMC & Analytical Development Summit returned this August to Boston. 70+ industry leaders united at this unique forum dedicated to CMC and Analytical Experts.  

Across 3 days, senior leaders leveraged knowledge and shared thought-leadership focused on improving analytical characterization, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind. 

Built with experts from AstraZeneca, Alexion Pharmaceuticals, Biogen, drug development protocols were revolutionized by keeping our finger on the pulse at this hotly anticipated summit.

https://eehw.net/wp-content/uploads/sites/781/2022/04/cropped-Oligos-Peptides-Formulation-Process-Development-1.png

Explored analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance 

https://eehw.net/wp-content/uploads/sites/781/2022/04/cropped-Oligos-Peptides-Formulation-Process-Development-1.png

Overcame the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development 

https://eehw.net/wp-content/uploads/sites/781/2022/04/cropped-Oligos-Peptides-Formulation-Process-Development-1.png

Got interactive in roundtable discussions, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape 

https://eehw.net/wp-content/uploads/sites/781/2022/04/cropped-Oligos-Peptides-Formulation-Process-Development-1.png

Facilitated cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications 

https://eehw.net/wp-content/uploads/sites/781/2022/04/cropped-Oligos-Peptides-Formulation-Process-Development-1.png

Turbocharged novel and complex oligonucleotide development in an in-depth workshop outlining CMC, Analytical Characterization and Impurity Control of conjugates